

# Straumann Holding AG

**CORE HOLDING\***

Recommended since 06.05.20

27.02.2024




<b>Country</b> CH	<b>Market capitalization (bn)</b> CHF 23,6	<b>Perf. since reco. (%)</b>
<b>Sector</b> Health Care	<b>Free float</b> 66,7%	Straumann Holding AG 100,2
<b>Factset</b> STMN-CH	<b>Closing price</b> CHF 148,00	Sector 21,0
<b>ISIN</b> CH1175448666	<b>ESG Risk score*</b> 22,4 Medium risk	



\*From 2015, B&Cie separates its investment recommendations into Core Holdings (higher organic growth potential, high free cash flow, ROCE in excess of the cost of capital and balance sheet efficiency throughout the cycle) and Satellite Recommendations, which do not meet the above criteria but are likely to outperform in the short-to-medium term.

## Profile

Straumann was founded in 1954 as a research institute originally focusing on the watchmaking industry. The group subsequently evolved to specialise in dental implants from 1974. Through a policy of targeted acquisitions, Straumann diversified into dental supply and equipment, becoming a key player in the sector. Implants account for 58% of the group's sales, restorative solutions 28% and other activities (biomaterials, scanner hardware, software and clear aligners) 14%.



Source: Factset

## Market - competition - positions - barriers to entry

The dental supply and equipment market is valued at CHF 27-29bn, with growth averaging c. 4-5% a year, buoyed by population expansion and innovation. Straumann ranks sixth in the market with a 6% share but is market leader in dental implants, where it has a 26% share, ahead of Envista.


## Investment case

- After initially specialising in high-quality dental implants, Straumann diversified by expanding its presence into markets offering a more buoyant growth outlook. Through this strategy, the group has been able to establish itself as a key player in esthetic dentistry. Through targeted acquisitions, the group has expanded its presence in dental implants by offering more affordable solutions, allowing access to fast-growing emerging markets, and has moved into CAD/CAM restorative solutions (digital design and manufacture of dental prosthetics) and orthodontics, with clear teeth aligners (mouthguards). Penetration is still low in these segments, which thus offer significant growth potential.
- Expansion in these markets and constant innovation will enable the group to extend its presence and to pursue growth which we estimate at 11% on average/year over the medium-to-long term, ahead of underlying market growth.
- Nevertheless, the business is sensitive to economic trends and their impact on consumer confidence, implying temporary postponements of elective procedures in times of recession due to lack of reimbursement. For 2024, the company expects organic growth of +7-9%, which remains below the long-term average, and persistent currency pressure on operating margin, estimated at 24-25% (vs. 25% in 2023).
- Straumann is a long-term growth stock in the Healthcare sector. With a strong balance sheet and relatively low gearing, the Group is in a position to pursue its development.

## ESG - risks and key points

- Straumann's level of ESG risk is high with ESG issues management in line with the sector. Nevertheless, the company has not experienced any major controversies in the past.
- As a supplier of dental implants, prostheses and biomaterials, Straumann must guarantee the quality and safety of its products to avoid any harm to patients. Design or manufacturing errors could lead to product recalls and litigation.
- Given the importance of innovation and competition in the industry, the Group must be able to attract and train highly qualified professionals.

## ESG risk vs. universe & sector (percentile)\*



Source: Sustainalytics

## Valuation\*\* in CHF

Current price	Value Bordier Scenario
148	140

Our scenario assumes Swiss 10-year yields rising to 1.75%; sales growth averaging 11% a year; an EBITDA margin improvement towards 36% at the end of the period.


\*\* The theoretical value reflects the company's business model, our baseline growth and profit scenario and market data, exogenous to the company (risk-free rate and equity risk premium). It does not in itself constitute a target price.

**"Bordier Core Holding" indicators**

In millions of CHF	2022	2023	2024e	2025e	2026e
<b>Sales revenue</b>	<b>2 321</b>	<b>2 412</b>	<b>2 569</b>	<b>2 877</b>	<b>3 395</b>
<b>Sales growth %</b>	<b>13,5%</b>	<b>3,9%</b>	<b>6,5%</b>	<b>12,0%</b>	<b>18,0%</b>
<i>a/w organic</i>	15,0%	9,8%	9,5%	12,0%	18,0%
<b>EBIT adjusted</b>	<b>603</b>	<b>606</b>	<b>642</b>	<b>754</b>	<b>934</b>
<b>% of sales</b>	<b>26,0%</b>	<b>25,1%</b>	<b>25,0%</b>	<b>26,2%</b>	<b>27,5%</b>
<b>Net income</b>	<b>482</b>	<b>440</b>	<b>483</b>	<b>584</b>	<b>742</b>
<b>Adjusted EPS</b>	<b>3,02</b>	<b>2,76</b>	<b>3,03</b>	<b>3,66</b>	<b>4,65</b>
Adjusted EPS growth	6,5%	-8,6%	9,7%	20,9%	27,0%
<b>Capex/Sales</b>	<b>8,4%</b>	<b>7,8%</b>	<b>5,0%</b>	<b>5,0%</b>	<b>5,0%</b>
Free cash-flow	220	317	465	544	670
<b>FCF/Sales</b>	<b>9,5%</b>	<b>13,1%</b>	<b>18,1%</b>	<b>18,9%</b>	<b>19,8%</b>
Dividend per share	0,80	0,85	0,78	0,95	1,21
<b>Dividend yield</b>	<b>0,8%</b>	<b>0,6%</b>	<b>0,5%</b>	<b>0,6%</b>	<b>0,8%</b>
<b>ROCE - WACC</b>	<b>22,7%</b>	<b>16,5%</b>	<b>17,9%</b>	<b>17,0%</b>	<b>17,3%</b>
<b>ROE (%)</b>	<b>26,0%</b>	<b>24,0%</b>	<b>22,3%</b>	<b>22,5%</b>	<b>23,5%</b>
<b>Net debt/Ebitda</b>	<b>2,0%</b>	<b>5,8%</b>	<b>-37,5%</b>	<b>-78,8%</b>	<b>-111,2%</b>

Source: Factset, Bordier estimates

**Sales breakdown - 12/2022**



**Ratios**

	<b>Straumann Holding AG</b>	<b>Sector</b>	<b>Stoxx Europe 600 Market</b>
<b>PE (x)***</b>		Health Care	Stoxx 600
2023	49,1	19,8	14,4
2024e	48,9	18,4	13,8
2025e	40,4	16,1	12,5
<b>P/B (x)***</b>			
2023	11,8	3,7	2,0
2024e	10,9	3,5	1,9
2025e	9,1	3,2	1,7
<b>Beta (2Y, daily) vs market:</b>			1,29

\*\*\*) The valuation ratios set out are provided for information only. They do not constitute the criteria based upon which Core Holdings are selected, and may present significant premi-ums representing the quality of the company's business model.

**Governance and ownership structure**

Since 2020 - CEO Guillaume Daniellot

**Key shareholders (if any):**

Thomas Straumann (Vice-Chairman of the Board of Directors) owns 16.9% of the capital; Rudolf Maag 11.5%; Simone Maag de Moura Cunha 3.7%; Gabriella Straumann 3%.

**Any special characteristics of ownership (multiple voting rights, controlling holding company, shareholders' agreements)**

None

**Agenda**

30 Apr. 2024: Q1 sales / 14 Aug. 2024: Half-year results  
29 Oct. 2024: Q3 sales

**Glossary**

**ESG Risk Score**

At B&Cie, we take particular care to ensure that the companies in which we recommend investing are sustainable. Accordingly, our selection process takes account of risks relating to environmental, social and governance (ESG) issues. This approach is underpinned by research from Sustainalytics, the global leader in ESG and corporate governance analysis, whose methodology aims to identify major controversies and risks and assess a company's ESG risks relative to both its sector and the investment universe as a whole. The corresponding score is expressed as a percentile: the lower the overall risk score, the lower the risk within the investment universe.

**b-Digital, b-Transition & b-Well**

Over and above the conventional geographical and sectoral approaches to asset management, at B&Cie we believe the world of tomorrow is being shaped by structural trends. We have identified three main megatrends: ongoing digital globalisation of the economy; economic transition, particularly in the energy sector; and the quest for wellness. We believe selecting and investing in companies that play an active role in these transformations should lead to more resilient portfolios that generate higher long-term returns. Our investment recommendations in the digital globalisation space are labelled "b-Digital", those in the economic transition space "b-Transition" and those in the wellness space "b-Well". A given recommendation may fall under more than one theme, in which case it will carry the relevant matching labels.

*This document has been issued for information purposes and is exclusively supplied by Bordier & Cie SCmA in the framework of an existing contractual relationship with the recipient of this document. The views and opinions contained in it are those of Bordier & Cie SCmA. Its contents may not be reproduced or redistributed by unauthorized persons. The user will be held liable for any unauthorized reproduction or circulation of this document, which may give rise to legal proceedings. All the information contained in it is provided for information only and should in no way be taken as investment, legal or tax advice provided to third parties. Furthermore, it is emphasized that the provisions of our legal information page are fully applicable to this document and namely provisions concerning the restrictions arising from different national laws and regulations. Consequently, Bordier Bank does not provide any investment services or advice to "US persons" as defined by the Securities and Exchange Commission rules. Furthermore, the information on our website - including the present document - is by no mean directed to such persons or entities.*